NYXH Nyxoah

Nyxoah Announces Participation in the Stifel 2021 Virtual Healthcare Conference

Nyxoah Announces Participation in the Stifel 2021 Virtual Healthcare Conference



Nyxoah Announces Participation in the Stifel 2021 Virtual Healthcare Conference

Mont-Saint-Guibert, Belgium. – November 3, 2021, 10:30 pm CET / 4:30 pm ET - Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Olivier Taelman, Chief Executive Officer, will participate at the Stifel 2021 Virtual Healthcare Conference on Monday, November 15, 2021, with a virtual fireside chat at 4:00 pm CET/10:00 am ET.

A live webcast and replay of the fireside chat will be available on the Company’s investors relations website at 

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE-Mark indication approval to treat Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit 

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Contacts:

Nyxoah

Jeremy Feffer, VP IR and Corporate Communications 



Gilmartin Group

Vivian Cervantes



Attachment



EN
03/11/2021

Underlying

NYXHNyxoah

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nyxoah

 PRESS RELEASE
Free
NYXH NYXOAH

Nyxoah Obtient des Engagements de Financement pouvant atteindre U.S. $...

Nyxoah Obtient des Engagements de Financement pouvant atteindre U.S. $77 Millions pour Supporter la Commercialisation de Genio aux États-Unis INFORMATIONS PRIVILÉGIÉESINFORMATIONS RÉGLEMENTÉES Nyxoah Obtient des Engagements de Financement pouvant atteindre U.S. $77 Millions pour Supporter la Commercialisation de Genio aux États-Unis Les financements consistent des investissements d’equity, notamment de ResMed, Cochlear et le Chairman et le management de Nyxoah, et une obligation convertible. Mont-Saint-Guibert, Belgique – 14 novembre 2025, 8h00 CET / 2h00 ET – Nyxoah SA (Euronext Bruxell...

November 14, 2025 1 EN
 PRESS RELEASE
Free
NYXH NYXOAH

Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Driv...

Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio INSIDE INFORMATIONREGULATED INFORMATION Correction and ReplacementNyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio Financings are comprised of equity investments, including from Cochlear, Resmed and Nyxoah’s Chairman and Management, and a convertible bond. This press release replaces the press release issued on November 13, 2025, at 10:11 pm CET / 4:11 pm ET in order to replace and correct the gross proceeds of the private placemen...

November 14, 2025 1 EN
 PRESS RELEASE
Free
NYXH NYXOAH

Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Driv...

Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio INSIDE INFORMATIONREGULATED INFORMATION Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio Financings are comprised of equity investments, including from Cochlear, Resmed and Nyxoah’s Chairman and Management, and a convertible bond. Mont-Saint-Guibert, Belgium – November 13, 2025, 2025, 10:11pm CET / 4:11 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the develo...

November 13, 2025 1 EN
 PRESS RELEASE
Free
NYXH NYXOAH

Nyxoah Reports Third Quarter 2025 Financial and Operating Results

Nyxoah Reports Third Quarter 2025 Financial and Operating Results REGULATED INFORMATION Nyxoah Reports Third Quarter 2025 Financial and Operating Results US launch off to a strong start. First commercial Genio implants completed with widespread payer coverage drives initial revenue. Mont-Saint-Guibert, Belgium – November 13, 2025, 10:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financia...

November 13, 2025 1 EN
 PRESS RELEASE
Free
NYXH NYXOAH

Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Tr...

Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Troisième Trimestre 2025 INFORMATIONS RÉGLEMENTÉES Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Troisième Trimestre 2025 Lancement réussi aux États-Unis. Les premières implantations commerciales de Genio, largement prises en charge par les organismes payeurs, génèrent les premiers revenus. Mont-Saint-Guibert, Belgique – 13 novembre 2025, 22h10 CET / 16h10 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), une société de technologie médicale développant des alternatives t...

November 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch